Search
for
Sort by
Research 151–180 of 1000+
- Investigator‐blinded, controlled, and randomized comparative study on 1565 nm non‐ablative fractional laser versus 5% minoxidil for treatment of androgenetic alopecia
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- Non-hemorrhage-related adverse effects of rivaroxaban
- Comparison of a New 5% Minoxidil Foam and Rogaine® in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Dermatological adverse events with taxane chemotherapy
- Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Malignancy and Cancer Treatment-Related Hair and Nail Changes
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Comprehensive Study of Drug-Induced Pruritus Based on Adverse Drug Reaction Report Database
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- En pacientes jóvenes, el uso de finasteride podría asociarse con mayor riesgo de ansiedad, depresión y eventos adversos relacionados con el suicidio
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use
- Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
- A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
- Utility of azathioprine, methotrexate and cyclosporine as steroid‐sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients
- 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Attenuates the Adverse Effects of Glucocorticoids on Dermal Papilla Cells
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions